Identification of oncogenic long noncoding RNA SNHG12 and DUXAP8 in human bladder cancer through a comprehensive profiling analysis

Abstract

Bladder cancer is a common urological malignancies world-wide. Recently, a growing number of evidence have highlighted the importance of long noncoding RNAs (lncRNAs) in multiple cancers development and progression. However, the expression pattern of lncRNAs in bladder cancer and their underlying function remain poorly understood. To identify lncRNAs profile alterations and uncover valuable lncRNA candidates for bladder cancer diagnostic, we conducted a comprehensively lncRNAs profiling analyses and explored their clinical relevance using The Cancer Genome Atlas (TCGA) data and three independent microarray profiling data from the Gene Expression Omnibus (GEO). After annotation and analyses of these data, we found that lots of lncRNAs were dysregulated in bladder specimen when compared with normal control specimen. In addition, we found that differential expression of these lncRNAs is accompanied by genomic variations, including genome loci copy number deletion or amplification. Importantly, a part of these lncRNAs are related to bladder cancer patients outcome, such as SNHG10, SNHG12 and LINC00115. Finally, we validated two of these lncRNAs' (DUXAP8 and SNHG12) function in bladder cancer cells by down-regulating their expression with siRNAs, and found that down-regulation of DUXAP8 and SNHG12 could inhibit bladder cancer cells proliferation in vitro. In summary, this study demonstrated that a lot of lncRNAs are dysregulated in bladder cancer, and might provide useful lncRNAs resource for potential prognostic or diagnostic markers for this disease.

A comprehensive analysis of coding and non-coding transcriptomic changes in cutaneous squamous cell carcinoma

“…Although many lncRNAs display highly lineage and cell type-specific expression pattern, we observed an increased expression of several lncRNAs dysregulated in a broad range of solid tumors, such as MIR31HG, which regulates senescence, as well as CYTOR (LINC00152), PVT1, HOXA-AS2 and SNHG12, which can regulate various cancer hallmarks 25,28,46,47 . Moreover several lncRNAs, reported to be upregulated in the primary and metastatic cSCC cell lines compared to progenitor keratinocytes 48 (e.g.…”

“…The most upregulated lncRNA in cSCC was RP11-493L12.5 (46.77-fold), while the most www.nature.com/scientificreports www.nature.com/scientificreports/ downregulated one was KB-1410C5.3/lnc-GRHL2 ( 0.005-fold). Of note, a number of lncRNAs with broad oncogenic (SNHG12, CASC9, LUCAT1 and PVT1) or tumor suppressor (such as TINCR) function were also identified to be differentially expressed in cSCC [25][26][27][28] .…”

TGF‐β‐activated lncRNA LINC00115 is a critical regulator of glioma stem‐like cell tumorigenicity

“…Transforming growth factor b (TGF-b) is a multifunctional cytokine and plays important functions in regulating GBM progression and GSC self-renewal [8][9][10][11]. High TGF-b activity confers poor prognosis in glioma patients [12].…”

Long non-coding RNA LINC00115 contributes to the progression of colorectal cancer by targeting miR-489-3p via PI3K/AKT/mTOR pathway

“…Here, we rstly reported lncRNA LINC00115 as a novel cancer-promoted regulator in CRC. LINC00115 was originally reported in lung cancer as a potential prognostic biomarker [20]. In another study, LINC00115 was identi ed to be a critical regulator of glioma stem-like cell tumorigenicity [21].…”